Table of Content

1 Key Insights

2 Executive Summary of Hyperkalemia

3 Disease Background and Overview: Hyperkalemia
3.1 Introduction
3.2 Symptoms of Hyperkalemia
3.3 Causes of Hyperkalemia
3.3.1 Pseudohyperkalemia
3.3.2 Increased Potassium Intake
3.3.3 Cellular shift
3.3.4 Disturbance in Renal Potassium Excretion
3.3.5 Decreased distal delivery of sodium
3.3.6 Mineralocorticoid deficiency
3.4 Pathophysiology of Hyperkalemia
3.4.1 Hyperkalemia from trans-cellular potassium shifts
3.4.2 Hyperkalemia from defective potassium excretion in the distal nephron
3.4.3 Hyperkalemia from defective extrarenal potassium excretion
3.5 Consequences of Hyperkalemia
3.5.1 Cardiac dysrhythmia: mechanism
3.5.2 Peripheral neuropathy
3.5.3 Renal tubular acidosis
3.5.4 Consequences of hyperkalemia in patients receiving dialysis
3.6 Diagnosis of Hyperkalemia
3.6.1 Interviews
3.6.2 Physical examination
3.6.3 Blood test
3.6.4 Urinalysis
3.6.5 Electrocardiography

4 Patient Journey

5 Epidemiology and Patient Population
5.1 Key Findings
5.2 KOL Views
5.3 Epidemiology Methodology

6 Japan Epidemiology
6.1 Assumptions and Rationale
6.1.1 Total Diagnosed Prevalent Population of Hyperkalemia in Japan
6.1.2 Gender-specific Diagnosed Prevalent of Hyperkalemia in Japan
6.1.3 Age-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan
6.1.4 Severity-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan
6.1.5 Comorbidities-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan

7 Current Treatment and Medical Practices
7.1 Treatment Algorithm

8 Unmet needs

9 Marketed Drugs
9.1 Lokelma (Sodium zirconium cyclosilicate): AstraZeneca
9.1.1 Drug Description
9.1.2 Regulatory Milestones
9.1.3 Clinical Development
9.1.4 Safety and Efficacy
9.1.5 Product Profile

10 Emerging Drugs
10.1 Key Cross Competition
10.2 ZG-801 (Patiromer/Veltassa): Zeria Pharmaceutical/Vifor Pharma
10.2.1 Product Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 RDX013: Ardelyx
10.3.1 Product Description
10.3.2 Other Developmental Activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile

11 Hyperkalemia: Japan Market Analysis
11.1 Key Findings
11.2 Market Methodology
11.3 Key Market Forecast Assumptions

12 Japan Market Outlook
12.1 Japan Market Size
12.1.1 Total Market size of Hyperkalemia in Japan
12.1.2 Market Size of Hyperkalemia by therapies in Japan

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Reimbursement and Market access

17 Appendix
17.1 Bibliography
17.2 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight



List of Figures


Figure 1 Serum Potassium Levels in Hyperkalemia
Figure 2 Maintenance of differential sodium and potassium concentration between cells and surrounding extracellular fluid
Figure 3 Symptoms of Hyperkalemia
Figure 4 Pharmacologic agents and conditions that can lead to hyperkalemia
Figure 5 Pathogenesis of hyperkalemia: mechanisms in the distal nephron.
Figure 6 Mechanism of cardiac arrhythmia in hyperkalemia
Figure 7 KOL Views
Figure 8 Total Diagnosed Prevalent Population of Hyperkalemia in Japan (2018–2030)
Figure 9 Gender-specific Diagnosed Prevalent of Hyperkalemia in Japan (2018–2030)
Figure 10 Age-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan (2018–2030)
Figure 11 Severity-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan (2018–2030)
Figure 12 Comorbidities-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan (2018–2030)
Figure 13 Hyperkalemia management algorithm
Figure 14 Unmet needs
Figure 15 Market Size of Hyperkalemia in Japan, USD Millions (2018–2030)
Figure 16 Market Size of Hyperkalemia by Therapies in Japan, in USD Million (2018–2030)
Figure 17 Market Drivers
Figure 18 Market Barriers
Figure 19 SWOT analysis


List of Tables


Table 1 Summary of Hyperkalemia, Market, Epidemiology, and Key Events (2018–2030)
Table 2 Total Diagnosed Prevalent Population of Hyperkalemia in Japan (2018–2030)
Table 3 Gender-specific Diagnosed Prevalent of Hyperkalemia in Japan (2018–2030)
Table 4 Age-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan (2018–2030)
Table 5 Severity-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan (2018–2030)
Table 6 Comorbidities-specific Diagnosed Prevalent Cases of Hyperkalemia in Japan (2018–2030)
Table 7 Lokelma; Clinical Trial Description, 2021
Table 8 Comparison of emerging drugs under development
Table 9 ZG-801, Clinical Trial Description, 2021
Table 10 RDX013, Clinical Trial Description, 2021
Table 11 Key Market Forecast Assumptions for Veltassa (Patiromer)
Table 12 Key Market Forecast Assumptions for Lokelma
Table 13 Japan Market Size of Hyperkalemia in USD Million (2018–2030)
Table 14 Market Size of Hyperkalemia by therapies in Japan, in USD Million (2018–2030)